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Introduction:
 
 Chronic Bronchitis is a serious and costly
health problem. Prevalence is estimated at 45 per 10,000
persons in the United Kingdom. Approximately £120,000
would be saved for every 100 hospital admissions
avoided. A reduction in acute exacerbations of chronic
bronchitis (AECB), treatment failures, and subsequent
hospital admission could have a significant impact on
the burden of AECB borne by secondary care facilities
in the UK National Health Service (NHS).
 
Objective: 
 
The aim of this study is to provide an eco-
nomic assessment of the direct cost to the health care
system associated with the management of chronic
bronchitis and its acute exacerbations.
 
Design:
 
 A prevalence-based, excess-cost-of-illness anal-
ysis is undertaken from the perspective of the UK NHS.
Disease prevalence data, primary health care resource
utilization, hospital inpatient and outpatient resource
utilization, and costs of health care were taken from a
variety of data sources, including a large UK national
survey of general practice (GP) consultations, the Gen-
eral Practice Research Database, a survey from a single
NHS hospital trust, and the national health-care re-
source and cost statistics.
 
Results:
 
 From 1994 to 1995, approximately 233,000
cases of chronic bronchitis were detected in the persons
aged 45 and older in the United Kingdom. Prevalence
peaked at 204 per 10,000 in the group of subjects aged
75 to 84 years. During that same period, the total excess
cost of primary care associated with AECB was calculated
at £35.7 million. The largest component of primary care
costs was the excess cost of all prescription medicines,
which totaled £27.8 million. The excess cost attributed
to antibacterial and respiratory prescription medica-
tions alone was estimated at £9 million. Excess costs at-
tributed to GP consultations and hospital emergency
room visits were £6.5 million and £1.3 million, respec-
tively. The excess costs arising from inpatient hospital
episodes included £8.3 million for hospital admissions,
£660,000 for outpatient costs, and £225,000 for day care.
 
Conclusions:
 
 These results suggest that improving the
management of AECB with the objective of reducing
the number of AECB treatment failures and the associ-
ated hospital admissions could significantly reduce ex-
penditures by the UK NHS.
 
Keywords:
 
 acute exacerbations of chronic bronchitis,
chronic bronchitis, cost of illness, health economics.
 
Introduction
 
Chronic bronchitis, which forms part of the group
of diseases classified as chronic obstructive pulmo-
nary disease (COPD), is a major disease in its own
right and has an estimated overall prevalence of
45 cases per 10,000 people in the United King-
dom. Prevalence increases with age, rising from
approximately 7.5 per 10,000 in persons aged 25
to 44 years to over 65 per 10,000 in persons aged
45 to 64 years, and peaks at over 200 per 10,000
in persons aged 75 to 84 years. Although a 14%
increase has been reported in the prevalence of all
respiratory disorders during the 10-year periods
from 1981/1982 to 1991/1992, the prevalence of
chronic bronchitis has fallen by approximately 30%
in males and approximately 10% in females [1].
Despite a decrease in prevalence, chronic bronchi-
tis remains a serious health problem with a major
economic impact on the health-care system.
The diagnosis of chronic bronchitis is based on
history and clinical assessment. The disease is highly
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correlated with a history of cigarette smoking and
previous bronchial infections. It is a chronic con-
dition with recurrent exacerbations, the majority
of which are caused by bacterial infection. Treat-
ment of chronic bronchitis and the acute exacer-
bations of chronic bronchitis (AECB) is relatively
straightforward, the first-line of treatment being
antibacterial agents; however, increasing resis-
tance to these agents has been noted [2]. Such re-
sistance, which has been linked to the overall use
of antibacterial drugs, can result in first-line treat-
ment failure with a consequent impact on the
management of AECB [3]. Possible causes of first-
line treatment failure include inappropriate anti-
bacterial treatment, either because an unsuitable
antibiotic was chosen or an incorrect dosage was
used. Treatment failure can lead to substantial
health-care costs [4].
There have been few economic studies of lower
respiratory tract infections (LRTIs), of which AECB
is an important contributor, along with commu-
nity-acquired pneumonia. Data published on the
health economics of AECB are even more limited.
One prevalence-based burden-of-illness study esti-
mated direct National Health Service (NHS) costs
of community-acquired LRTI at £1364 million, or
approximately 0.5% of the NHS budget, incurred
in treating 16.3 million cases in 1992–1993 [5].
Bronchitis alone accounted for approximately 30%
of this cost. Backhouse et al. [4] used a decision-
analytic modeling approach to study the cost-effec-
tiveness of alternative antibiotic regimens in the
treatment of AECB. Given the shortcomings of the
data, extensive sensitivity analysis was undertaken.
The analysis determined that the main cost drivers
were the cost of the drug therapy and the cost of
treatment failure, in terms of additional use of the
health service.
The aim of this study is to provide a more com-
plete economic assessment of direct costs to the
health-care system for management of AECB and
the consequences of treatment failure. To do so,
an excess-cost-of-illness analysis was undertaken
from the perspective of the UK NHS [6].
 
Methods
 
Cost-of-Illness Analysis
 
Two main methods can be used to calculate the
cost of illness: The “top-down” approach uses ag-
gregate data on hospital admissions, outpatient
clinics, general practice (GP) consultations, and
other readily available national data that can be
attributed to the disease under study. The second,
or “bottom-up” approach uses prevalence data
combined with data on disease and treatment
probabilities to construct an estimate of the an-
nual volume of treatments and resultant costs.
Cost-of-illness studies are a means of calculating
the resource impact of a disease on a population,
and the analysis can be undertaken on a prevalence
or incidence basis. A prevalence approach, which
focuses on the average number of cases treated
during a given time interval—1994–1995 in this
case—was adopted for this analysis. Cost-of-illness
studies based on incidence of a disease are able to
show the consequences of changes in the incidence
of the disease. This type of study is best used when
investigating a preventive measure wherein the ben-
efits can be measured in terms of numbers of cases
avoided. Cost-of-illness studies, based on disease
prevalence, estimate the total annual health-care ex-
penditure and are relevant for chronic diseases for
which treatment is needed over long periods of time.
This consideration led us to use the prevalence-
based approach in this study.
The current analysis is mainly concerned with
the excess cost of primary-care treatment and the
costs of treatment failure. The concept underlying
this approach is that the true burden of a disease is
the excess burden imposed on society by that dis-
ease. This excess burden results from increased use
of health-care resources, which exceeds use of such
resources by the general population. This is most
important in instances where, for example, diag-
nosis is difficult or where attribution of the health-
care services used to the disease under study is not
straightforward. Under such circumstances, it may
be misleading to identify only recorded cases of the
disease for the purposes of a cost-of-illness analy-
sis. It is more justifiable, in the sense that it is more
inclusive, if the excess rate of health-care utiliza-
tion is identified. In this analysis, the diseased pop-
ulation is identified and compared with an equiva-
lent healthy population and excess likelihood of
health-care utilization is calculated.
Given that the authors are particularly concerned
with the management of chronic bronchitis and its
acute exacerbations, as well as with treatment fail-
ure, we make use of a variant of the “bottom-up”
approach. We identified the health-care resources
used in treatment and management of chronic bron-
chitis and AECBs and obtained costs for the identi-
fied resources. The prevalence of chronic bronchitis
is taken from a large national study of GP consulta-
tions, and this information allowed us to identify
our population of interest [1]. The prevalence rate is
based on individuals who consulted a GP practice at
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least once for the treatment of chronic bronchitis.
Excess costs were calculated as total direct costs
over and above costs incurred by the background
population using the methodology described by
Fenn, Gray, and McGuire [6].
Treatment failure is defined as hospitalization,
which is relatively simple but effective. Although
some treatment failures are undoubtedly ad-
dressed in the primary-care setting, these are diffi-
cult to identify. Hence, we rely on a measure that
represents the most expensive consequences of
failure and has the greatest impact for both the pa-
tient and the health-care system. A total annual
cost of illness arising from the management of
chronic bronchitis and its acute exacerbations is
obtained by associating treatment costs with the
estimated volume of resources used.
 
Primary-Care Resource Use
 
The volume of resource use resulting from the
treatment of chronic bronchitis and its acute exac-
erbations is based on a calculation of the increased
probability of using primary-care facilities [6].
This excess risk is calculated from data taken from
the General Practice Research Database (GPRD),
which collects data from a panel of approximately
500 GP practices throughout England and Wales
[7]. The total population covered is approximately
3.5 million. In England and Wales, this represents
coverage of approximately 6% of the population.
Studies have revealed that the database is broadly
representative of the population of England and
Wales, although there is a slight under-representa-
tion of smaller-sized practices and inner-city Lon-
don practices. Otherwise, all data appear compa-
rable with that collected from a variety of national
sources [8]. For our purposes, it is important to
note that GP returns to the GPRD may not list all
consultations. In particular, where a patient is pre-
scribed long-term treatment for a chronic condi-
tion, only the first consultation is recorded, al-
though the GP may choose to record more than
this. A diagnosis of chronic illness can appear only
once in a patient’s record. Moreover, the GP is not
required to record risk data such as smoking sta-
tus, so this information is largely incomplete. Not-
withstanding such caveats, patient consultation
rates for diseases such as asthma appear to be con-
sistent with epidemiological survey data [8].
We acquired data for 1994 and 1995 from the
GPRD on individuals aged 40 years and over. A
total of 2477 individual records was collected,
with 1239 individuals recorded as having a diag-
nosis of chronic bronchitis (ICD-9 code 491) at
some point from 1990 to 1993. Another 1238 in-
dividuals with no diagnosis of chronic bronchitis
from the same time period were matched on the ba-
sis of age, gender and GP practice against the bron-
chitis records. Given the dramatic increase in the
prevalence of chronic bronchitis in the group of 45
to 64 year olds, persons analysis was restricted to
persons aged 45 and older and undertaken for the
following age brackets: 45 to 54, 55 to 64, 65 to 74,
75 to 84, and over 85.
As noted above, only the first consultation must be
recorded for chronic diseases. Approximately 70% of
chronic bronchitis cases recorded no GP consultations
for any reason during the 2-year study period, indicat-
ing that diagnosis had been made at some prior
point. It should be noted, however, that in the case of
chronic bronchitis, a consultation for an acute exacer-
bation would most likely be noted, as it would repre-
sent a deterioration in the patient’s condition and
would require additional medication. Approximately
the same number of individuals in the matched com-
parison population also recorded no consultations for
any reason during the 2-year study period.
The background probability of a GP consulta-
tion for the nonchronic bronchitis population was
calculated using the matched comparison popula-
tion. The difference between the rate of consulta-
tion for the chronic bronchitis population and the
background probability yielded an estimate of the
excess probability of GP consultations in patients
with chronic bronchitis. The increased rate of GP
consultations was attributed primarily to the need
for respiratory and antibacterial prescriptions and
total prescriptions. Differences in referral rates for
chest X-rays, laboratory samples requested by GPs,
and emergency clinic visits were calculated using
similar methodology. Data for a period of two
years were collected to adjust for any seasonal ef-
fects which might arise in the analysis of this con-
dition, and these were converted to annual rates.
The cost of a GP consultation was estimated at
£9 in 1997–1998 prices [9]. The cost of prescrip-
tions arising from a consultation were estimated at
£10 for those relating to respiratory disease, £4
for antibiotics, and £9 for miscellaneous prescrip-
tions, all in 1997–1998 prices[ 10]. Also estimated
were costs for chest X-rays (£12), GP-requested
laboratory samples (£7), and emergency clinic vis-
its (£52), all of which were based on costs from a
number of NHS Trusts [11].
 
Secondary Health-Care Resource Use
 
To construct a more accurate a picture of second-
ary health care resource use, we used several pri-
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mary sources of data and validated the estimates
obtained. Hospital inpatient resource utilization
was estimated using the Hospital Episode Statis-
tics [10] and the CHKS publication on acute care
[12]. The Hospital Episode Statistics reports the
number of ordinary hospital admissions and ad-
missions to hospitals as day cases for diagnostic
reasons. However, because these reports do not
record length of stay for individual diagnoses, this
information was acquired from the CHKS publi-
cation and related to the UK Health Related
Grouping (HRG) on chronic obstructive airway
disease and bronchitis. HRG data were available
for two age groups: persons aged 75 years or older
and persons aged 75 years or younger.
This information was validated by comparison
with hospital statistics on chronic bronchitis alone
taken directly from a single NHS hospital trust
[13]. In this study sample, 77 cases had a primary
or the secondary diagnosis of chronic bronchitis.
We used data on attendance at a hospital outpa-
tient clinic from the same NHS hospital trust, as
more extensive national data were not available.
These data indicated an average of 1.22 outpatient
visits per AECB episode.
Information on unit costs for secondary health-
care resource use was collected from multiple
sources, as no single source was available. The
hospital costs were based on average costs taken
from a database of over 200 hospital trusts for
1997–1998 and published by the UK Department
of Health as reference price data [14]. The cost of
an inpatient stay in an acute- or mainly acute-care
facility was £1184 per case, with an average length
of stay of 7.9 days for the group of subjects under
age 75 and 10.3 days for the group of subjects
aged 75 and older. This is consistent with average
lengths of stay reported by CHKS of 7.7 days and
11.2 days, respectively, for these age groups [12].
The cost of a day case was estimated at £601 for
patients over age 75 and £561 for those under age
75. This was based on the Extra Contractual Re-
ferral (ECR) tariff for chronic obstructive pulmo-
nary disease or bronchitis as published by the UK
Department of Health in 1997–1998 prices. The
average cost of an outpatient visit was £77 based
on the department’s ECR tariffs, which reflect the
average cost of treatment [14].
 
Results
 
Table 1 reports the estimated total population over
age 45 with chronic bronchitis based on the popu-
lations of England and Wales and the prevalence
rates reported in the Fourth Morbidity Survey [1].
The total chronic bronchitis population is estimated
at approximately 250,000, with prevalence peak-
ing in the group of patients aged 75 to 84 years.
Table 2 reports the mean excess use of primary-
care resources resulting from the excess burden of
chronic bronchitis and AECBs derived from GPRD
data for 1993 and 1994. Table 3 reports the ex-
cess costs in 1997–1998 prices of primary care re-
sulting from the treatment of chronic bronchitis
and its acute exacerbations by age group. The to-
tal excess costs, as calculated by the relative likeli-
hood of health-care utilization by the chronic-bron-
chitis population as compared with the matched
control population, was £35.7 million in 1994–
1995 (at 1997–1998 prices). The largest compo-
nent of cost was the excess cost of all prescription
medicines, which totaled £27.8 million. This was
much higher than the next largest component of
excess cost, the GP consultations themselves, which
totaled £6.5 million. All age groups, apart from
the 85-years-and-older group, had a greater num-
ber of GP visits than the comparison population.
It is possible to infer that in the 85-and-older age
category, primary-care treatment of other diseases
took precedence over that of chronic bronchitis.
The next largest cost component was the excess
cost of emergency clinic visits. If prescriptions were
restricted to antibacterial and respiratory medica-
tions, the excess cost of chronic bronchitis and its
 
Table 1
 
Chronic bronchitis in persons aged 45 and older 
in England and Wales, 1994–1995
 
Age group
(years)
Population size
(thousands)
Prevalence per
10,000
Chronic bronchitis
population
45–54 6,758 65 43,927
55–64 5,081 65 33,027
65–74 4,481 193 86,483
75–84 2,816 204 57,446
85
 

 
970 124 12,028
 
Table 2
 
Excess resource use units in primary care for 
chronic bronchitis and acute exacerbations (annual per-
person mean in years 1994–1995)
 
Age groups (years) 45–54 55–64 65–74 75–84 85
 

 
Chest x-rays 0.03 0.08 0.10 0.06 0.01
Laboratory tests 0.04
 

 
0.01 0.02
 

 
0.06
 

 
0.04
ER Visits 0.28 0.12 0.02 0.13 0.00
GP Visits 4.10 4.51 3.60 1.46
 

 
0.30
Respiratory prescriptions 0.09 0.28 0.13 0.11 0.23
Anti-bacterial prescriptions 1.87 2.45 2.12 1.40 0.24
All prescriptions 15.22 18.65 19.33 7.96 11.35
Prescriptions excluding anti-
bacterial and respiratory 13.26 15.92 17.07 6.45 10.88
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acute exacerbations would be estimated at ap-
proximately £9 million. This is an extreme restric-
tion to place on the data and may be considered a
minimum cost estimate. The excess cost of labora-
tory tests is reported as a negative value for most
age groups, probably owing to empirical treat-
ment in the older age groups.
Table 4 records the direct costs arising from in-
patient hospital episodes associated with treat-
ment of chronic bronchitis. The direct cost of
treatment failure is £9.1 million, of which hospi-
talization is the largest component at £8.3 million.
Excess outpatient costs total £658,658, and day-
case care is approximately £224,629.
 
Discussion
 
This study calculated the excess cost of health-care
utilization arising from chronic bronchitis and con-
sequent treatment failure. The overall aggregate
cost amounted to approximately £45 million in
the year 1994–1995 for our estimated patient pop-
ulation of about 233,000. This figure represents be-
tween 0.1% and 0.2% of the UK NHS budget.
The aggregate consists of two elements, the excess
cost of exacerbations, totaling £35.7 million; and
the cost of treatment failure (defined as hospital-
ization), which totals £9.2 million. Whether all
the excess cost of health care utilization can be at-
tributed to chronic bronchitis is arguable. Given
that the excess cost was dominated by excess pre-
scription costs, we have also calculated an excess
cost based solely on antibacterial and respiratory
medications, which reduces the excess cost of pri-
mary care to around £9 million. This implies that
patients with chronic bronchitis have excess co-
morbidities and associated prescription drug costs.
A limitation of the present study was that the
study population could not be separated into smok-
ers and nonsmokers, given that the GPRD data did
not always include this information. Analysis based
on this characteristic would have been interesting,
but the absence of this information may have been a
major restriction. In the GP National Morbidity Sur-
vey researchers note that, although smoking is known
to reduce life expectancy, their survey did not show a
marked difference in GP consultation rates between
smokers and nonsmokers [1]. In fact, for men, the
likelihood of consulting during their survey period
tended to be lower for smokers than for nonsmokers.
For respiratory disorders, specifically, the odds ratio
for smokers consulting as compared with nonsmokers
was 0:9 for men and 1:1 for young females and 1:2
for elderly females. Therefore, the excess likelihood of
health care utilization, at least in the primary sector,
can be inferred to be broadly similar. Given that treat-
ment failure was defined as hospitalization in our
study, we must assume that such failure was as com-
mon for smokers as for nonsmokers.
Another limitation of this study involves the use
of data from existing sources. In some instances,
the data available were based on relatively small
 
Table 3
 
Excess costs of primary care for chronic bronchitis and acute exacerbations (£ 1997–1998)
 
Age groups(years) 45–54 55–64 65–74 75–84 85
 

 
Total
Chest x-rays 16,578 30,855 105,168 37,993 1,146 191,740
Laboratory Tests 12,416
 

 
2,257 9,105
 

 
23,533
 

 
3,675
 

 
7,945
ER visits 648,922 205,498 79,361 373,402 0 1,307,183
GP visits 1,620,885 1,339,236 2,805,173 752,319
 

 
32,647 6,484,967
Respiratory prescriptions 40,325 91,995 115,598 77,647 25,094 315,616
Antibacterial prescriptions 328,787 323,765 732,624 322,529 11,761 1,719,466
All prescriptions 5,240,853 4,731,135 13,290,290 3,332,867 1,178,186 27,773,330
Grand total* 35,749,275
 
*Grand total is based on “all prescriptions” category.
 
Table 4
 
Excess hospital costs for chronic bronchitis and acute exacerbations (£ 1997–1998)
 
Age group (years) 45–54 55–64 65–74 75–84 85
 

 
Total
Hospital admissions (N) 913 808 2391 2170 730
Day cases (N) 51 45 133 120 40
Outpatient visits (N) 1114 986 2917 2647 890
Cost per outpatient * £85,778 £75,922 £224,609 £203,819 £68,530 £658,658
Cost of hospital admissions* £1,080,992 £956,672 £2,830,944 £2,569,280 £864,320 £8,302,208
Cost of day cases* £28,611 £25,245 £74,613 £72,120 £24,040 £224,629
Grand total cost £9,185,495
 
*Total.
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sample sizes (e.g., average hospital outpatient vis-
its from a single NHS hospital trust). Therefore,
these estimates are potentially susceptible to bias
based on variability arising from small sample
sizes or from regional differences. However given
the lack of national data, this estimate is likely to
be the best currently available.
A previous UK prevalence-based burden-of-ill-
ness study estimated the total direct health care
costs of community-acquired LRTI [4]. AECBs
form part of the LRTI population, and the other
main contributor to this category is community-
acquired pneumonia. That study reported the ma-
jor cost driver was inpatient costs, followed by
costs attributed to GP visits. The methodology
used in the current study differed from the study
by Guest and Morris [5] in two important ways:
• Excess direct health-care costs were calculated
in the current study whereas total direct health-
care costs were calculated in the Guest study.
• Only LRTI patients with chronic bronchitis
were used in the current study whereas all
LRTI patients were used in the Guest study.
Nonetheless, similar results were found in the
two studies, with inpatient costs comprising the
majority of direct costs followed by costs incurred
from GP visits.
The potential exists for significantly reducing
NHS resource use by reducing AECB treatment
failures and any subsequent hospital admissions.
Some authors have advocated the use of more
effective therapies in the GP setting in order to
achieve this [15]. Economic evaluations of alterna-
tive antibiotics for AECB report that costs of treat-
ment failure are high and that these costs may be a
result of using antibiotics with lower efficacy [4].
Chronic bronchitis has a major health and eco-
nomic impact. This is a direct consequence of the
prevalence of the disease. The considerable eco-
nomic burden of chronic bronchitis and its exacer-
bations as demonstrated in this study could be re-
duced if the rate of treatment failure and subsequent
hospitalizations were addressed. Alternatively, pri-
mary prevention of risk factors for chronic bronchi-
tis such as smoking would have a long-term impact
on public health and a subsequent economic impact.
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